Jeena Sikho Lifecare Limited (NSE: JSLL, BSE: 544476) reported strong financial and operating performance for the quarter ended December 31, 2025, driven by rapid expansion across its Ayurveda healthcare services and products businesses, according to the company’s Q3 FY26 investor presentation.
Financial performance
Revenue from operations rose to ₹221.66 crore in Q3 FY26, compared with ₹115.69 crore in Q3 FY25 and ₹189.85 crore in Q2 FY26. This represented 92% year-on-year growth and 17% sequential growth.
EBITDA increased to ₹100.80 crore, up from ₹29.61 crore a year earlier and ₹92.06 crore in the previous quarter. The EBITDA margin stood at 45%, compared with 26% in Q3 FY25.
Profit after tax rose to ₹66.73 crore, compared with ₹13.21 crore in the year-ago quarter and ₹58.78 crore in Q2 FY26. The PAT margin was 30%, reflecting operating leverage and scale benefits. Basic earnings per share increased to ₹5.37 from ₹1.06 a year earlier.
Operating metrics
Patient volumes increased across formats in the quarter. OPD, COD and video consultation patients reached 4.34 lakh, up 247% year on year and 68% quarter on quarter. OPD patient volumes rose to 1.57 lakh, up 89% year on year.
In-patient department (IPD) volumes increased to 11,313, up 84% year on year. Video-call consultations reached 61,135, up 214% year on year. Day-care volumes increased to 18,977, reflecting growth across service delivery channels.
The company said the increase in patient volumes supported higher utilisation across hospitals, clinics and day-care centres.
Business mix and revenue streams
The company operates two verticals: Ayurveda healthcare services and Ayurveda healthcare products. For the nine months ended FY26, services contributed 49% of revenue and products contributed 51%. The products business carries high gross margins and supports cash generation, while services benefit from operating leverage as utilisation rises.
Network expansion and capacity
As of December 2025, Jeena Sikho operated 58 hospitals and 59 clinics and day-care centres across 23 states, covering more than 100 cities and towns. The company had 2,290 operational beds, with 475 beds in the pipeline and 510 beds recently added. Management said the capital-light, hub-and-spoke model supports rapid scale-up with lower capital intensity.
The company highlighted a pipeline of six facilities under development, which is expected to support further growth in patient volumes.
Annual performance trend
For FY25, revenue from operations stood at ₹469.07 crore, up from ₹324.41 crore in FY24. EBITDA for FY25 was ₹124.88 crore, compared with ₹92.99 crore in FY24. Profit after tax increased to ₹90.73 crore from ₹69.21 crore a year earlier, reflecting sustained growth over recent years.
Capital structure and cash flows
Total equity increased to ₹273.02 crore as of FY25, from ₹192.25 crore in FY24. Operating cash flow for FY25 was ₹68.63 crore. The company reported limited borrowings and highlighted a capital-light operating model.
Summary
Jeena Sikho Lifecare delivered strong top-line and bottom-line growth in Q3 FY26, supported by rising patient volumes, expanding capacity and operating leverage. The dual-vertical model, combining services and high-margin products, contributed to profitability. Continued expansion of hospitals and clinics is expected to support further growth in volumes and revenue in coming quarters.